Evidence-based laboratory medicine (EBLM) is an essential part of modern laboratory medicine practice. This review presents a guide for better understanding and implementing the EBLM process. The process of EBLM begins with development of a clinically relevant question. Tools for assisting in question formulation include the Patient Intervention Comparator and Outcome (PICO) or Case Assay Predicate and Outcome (CAPO) strategies. Locating evidence that addresses the question is performed using resources available on the internet. Systematic reviews that have objectively collated evidence addressing the question can be particularly useful. The evidence collected must be critically appraised using checklists developed for this purpose. Diagnostic performance of tests is frequently stated in terms of sensitivity, specificity, negative and positive predictive values, and the diagnostic odds ratio. Evaluating 95% confidence limits is important for interpretation. Likelihood ratios for tests in disease states are also important for converting pre-test probabilities to post-test probabilities using Bayes Theorem. Tools such as Receiver Operator Characteristic curves and Fagan's diagram are important analytical and visual aids. Laboratorians must give thoughtful consideration into conveying information to clinicians in a useful format. Evidencebased guidelines and collaboration with clinicians are important for development of local care paths. Auditing the effectiveness of implemented care paths is an important part of quality management. In conclusion, effective use of EBLM can benefit patients by helping laboratorians provide the best-available information in the clinically relevant time frame. Presenting the information appropriately maximizes clinical application of the best evidence.
Introduction
Critical evaluation of laboratory medicine procedures is a cornerstone of practice in modern professional life. This evaluation combines the principles of evidencebased laboratory medicine (EBLM) and the experience gained in integrating knowledge about tests and procedures in the context of speci¢c cases, patient populations and clinical scenarios. This experience is guided by successes, failures, the outcomes of our decisions as well as by evolving expertise. In everyday practice we frequently realize that there is 'much more darkness than light' in that many issues calling for decisions are not well supported by scienti¢c evidence. The fact is that laboratory practice demands that decisions be made with best-available evidence, even if it is incomplete and less than a perfect ¢t for the myriad of speci¢c issues and patient scenarios.
There is clearly much work to be done in e¡ectively disseminating and utilizing best evidence. This point was illustrated by McGlynn et al. 1 who examined the extent to which health-care standard processes are delivered in the United States of America. The investigators contacted a random sample of 6712 adults from 12 metropolitan areas and examined their medical records over the most recent two years. They used the collected information to evaluate the performance of 439 indicators of quality care. The ¢ndings were striking; only 54.9% (54.3--55.5%) of subjects received the recommended level of care. 1 Laboratory medicine and radiology testing did slightly better than average at 61.7%; however, this level of appropriate utilization must also be viewed as unsatisfactory. The authors concluded that de¢cits in utilizing best evidence identi¢ed in their study 'pose serious health threats to the American public'and strategies to reduce such de¢cits are warranted. 1 The process of EBLM represents a step towards reducing these de¢cits.
Laboratorians are skilled at characterizing the technical performance of tests and strategies. As indicated in Figure 1 , technical performance comprises the foundation for meaningful laboratory medicine information, evidence and interpretation. 2 Technical performance consists of accuracy, precision, analytical measurement range, clinical measurement range, interferences, specimen type and less well-de¢ned pre-analytic factors including biological variability and sample stability. 3 The reality is that these considerable technical e¡orts lack visibility by our clinical colleagues and patients because they are internal to our organizations. The assumption of quality by users of laboratory medicine services can be viewed as a compliment.
Although characterization and evaluation of technical issues is of critical importance, this review focuses on the more visible processes of evaluating the performance and potential clinical impact of laboratory procedures. Here we will focus on components of this process that include clinical indications for the test, how the test should be utilized clinically, and how the data may be discussed and presented with aids for interpreting laboratory procedures.
Think like the clinician
Saint Ambrose stated in about 370 AD that 'When in Rome do as the Romans'. This notion of not setting your own rules in another environment can be translated into modern laboratory medicine as 'When communicating with clinicians, one must think like a clinician. ' Laboratorians must learn and understand the perspective of the clinician. Clinicians usually practice in the context of a single patient; ¢rst and foremost they want tests that can de¢ne a speci¢c disease (not necessarily a pathological process associated with many conditions) and potentially re£ect on the underlying aetiology that can be targeted for therapy. Clinicians are rigorously trained to take a thorough history, carefully examine a patient's physical status and vital signs, and to be cognizant of changes from previous clinical encounters. In the context of acute health changes, the clinician develops a list of possible diagnoses or causes for the observed illness and assigns a probability to each. These probabilities, termed the 'pre-test probability' for each diagnosis, are equivalent to the prevalence of the disease in patients having the same characteristics, signs, symptoms, history and overall clinical picture. Only after estimating the pre-test probability does the properly trained clinician request testing from services such as Radiology, Pathology and/or Laboratory Medicine. After testing by the service is complete, the clinician can estimate the post-test probability using the pre-test probability and background knowledge of the test's performance characteristics for the patient population, for each diagnosis being considered.
Laboratory medicine is implicit in the process of selecting the appropriate tests and strategies for raising (ruling in) or lowering (ruling out) the likelihood of the diagnosis after estimation of the pre-test probability.
With the post-test probability in hand, the clinician must then decide the diagnosis and determine the disposition and treatment options in the context of the individual patient's medical history, other tests and personal preferences. If the laboratory test has no potential for impacting decisions regarding diagnosis, disposition or treatment, then performing the test was useless and should not be requested. Figure 2 outlines the process of EBLM. As indicated, the ¢rst step is formulating and stating the clinically relevant question. A clear understanding of the speci¢c patient scenario, pre-test probability and information need is essential.
Elements of evidence-based laboratory medicine

Question formulation
Physicians and other caregivers obtain laboratory medicine tests for individual patients to detect physiological derangement, to determine and monitor a derangement's magnitude, to rule in/rule out a diagnosis, to assess prognosis and to guide and monitor therapy or intervention. 4 Historically, laboratory medicine testing has been referred to as 'diagnostic testing', re£ecting the large number of studies that were conducted for evaluating the diagnostic value of lab tests, rather than their value in prognosis or in guiding intervention. Over the years, there has been increased utilization for addressing important questions regarding other applications. Of note, a Cochrane group has been convened on monitoring and management of chronic disease, an area in which laboratory medicine plays a central role. Table 1 
As indicated in
Finding the evidence
A fundamental resource for EBLM is the peer-reviewed literature. However, locating the most relevant literature can be very challenging. Structured question formulation, as indicated above, is useful for both focusing the clinical issue at hand as well as for serving as an aid for ¢nding evidence that addresses the question. Key words derived from the structure can be used to directly search the literature in the context of the clinical question. Perhaps the most widely available and useful resource for ¢nding evidence is PubMed, a service provided at no charge by the United States government. The internet address for PubMed is http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi. The Boolian logic terms AND, OR and NOT are used to combine key words, authors and terms to either limit or broaden the search strategy. Another useful tool that is frequently more speci¢c than PubMed is EMBASE, a commercial product from Elsevier. EMBASE can be particularly valuable for ¢nding non-English literature, and has ways to access citations that are not available with PubMed. There are other databases that are speci¢c for review articles; these include the Database of Abstracts of Reviews of E¡ects (DARE), which is part of the Cochrane Library http://www.Cochrane.org and Meta-analyses van DIagnostich ONderzoek (MEDION) (meta-analyses of diagnostic investigations).
Ask
Convert information needs into answerable, clinically relevant questions Track down the best evidence for answers Critically appraise the evidence for validity and usefulness (rate strength)
Apply results of this appraisal in laboratory practice
Evaluate (audit) performance
Find Appraise Act Audit Figure 2 An outline of the evidence-based laboratory medicine process Although there are numerous databases available electronically, it is important to recognize that the internet is a dynamic tool. Information can go out of date quickly, links may change and new databases may appear. A useful method for locating updated information can be found at http://www.cmwr.org/ ebm/; some databases listed here are free and some are provided at a cost; also, some databases are from a single source, while others are combined resources. Websites of professional organizations including the IFCC C-EBLM committee (http://www.fescc.org/divisions/ emd/c-eblm) and AACC (www.aacc.org) also contain useful information.
Those experienced in EBLM know that one should avoid searching and evaluating literature alone. Consulting experts in library science and those experienced in the ¢eld of interest can assist in ¢nding potentially useful information. Further, unpublished studies may be located by examining bibliographies of identi¢ed articles and literature from government institutions. A recent piece summarizes resources that provide useful information when conducting searches for relevant EBLM evidence. 5 Evaluating the literature A survey of diagnostic accuracy studies published in four major medical journals between 1978 and 1993 revealed that the methodological quality was modest at best. 6 A major problem identi¢ed was that full evaluation of the literature was impossible because many reports lacked information on essential elements of study design, conduct and data analysis for the diagnostic studies. 7 As in any type of research, £aws in study design can lead to biased results and inappropriately optimistic estimates of diagnostic accuracy compared with studies without such biases. 7 At the 1999 Cochrane Colloquium meeting in Rome, a working group on screening test methods discussed the poor methodological quality and substandard reporting of diagnostic test evaluations. Modelled after the successful CONSORT initiative, a project resulted from this discussion that was termed 'STAndards for Reporting of Diagnostic Accuracy', abbreviated to STARD. 8 STARD's primary objective was to improve the quality of reporting of diagnostic accuracy studies so that readers can better detect the potential for bias in a study and assess how generally the results may be applied in practice. 9 As an essential aid for helping to accomplish this objective, the STARD group developed a checklist (Table 2 ) and other tools to guide investigators in providing information about methods of patient recruitment, the order of test execution and the numbers of patients undergoing the test under evaluation, the reference standard or both. 9 These tools are also useful for evaluating the quality of studies as this is dependent on complete and accurate reporting. Many peer-review journals have embraced the STARD initiative, and there is evidence that the quality of reporting evidence regarding diagnostic accuracy has improved. 10 The STARD checklist, associated £ow diagram and further details on this initiative and tool are available on the web at http://www.consort-statement. org/stardstatement.htm.
Sources of bias
Bias is a temptation that must be strictly avoided in study design and conduct (as well as in other components of professional life). Table 3 describes some important sources of potential bias. 11 Publication bias refers to the notion that studies yielding positive ¢ndings are far more likely to be published in the peer-reviewed literature than studies yielding negative ¢ndings and is particularly important. Publication bias can limit the information that will be detected on literature search and is a major reason why e¡orts must be made to include and evaluate both published and unpublished negative studies in meta-analysis or systematic review. Publication bias can result in overly optimistic estimates of test performance in laboratory medicine or of treatment e¡ects in therapeutic studies. Although an e¡ort to locate unpublished data is recommended, there is always trepidation regarding these studies because they are not subjected to the rigors of the peer-review process. As a general practice, experts recommend that the e¡ects of unpublished studies and data on the overall conclusion be evaluated by performing separate meta-analyses with and without the unpublished studies to determine consistency. Reviewers and editors active in the peer-evaluation process must strive to evaluate whether submitted research is conclusive or not, rather than whether it is positive or negative.
Literature reviews
There are essentially two types of literature reviews, narrative and systematic, both of which represent retrospective, observational, intellectual endeavours that may be subject to systematic and random error. 12, 13 Essentially, the quality of a review depends on the extent to which e¡orts have been made to minimize sources of error and bias. The use of rigorous scienti¢c methods towards this e¡ort is a fundamental feature that distinguishes narrative reviews from systematic reviews. 12 Narrative reviews are commonly written by experts in the ¢eld who have a keen interest in the examined topic. This zealous interest is frequently accompanied by a particular bias developed over years of thought, research, study and usually direct involvement in the reviewed topic. On the one hand, narrative reviews can provide detailed insight into a ¢eld by an expert investigator and practitioner. However, narrative reviews are often developed using idiosyncratic analysis methods that represent a subjective appraisal and qualitative summary of data supporting the view of the expert author. Con£icting data are frequently discounted or excluded altogether. As a result, narrative reviews typically present broad discussion about aetiology, pathogenesis, diagnosis, clinical management and prognosis rather than addressing speci¢cally stated and focused clinical questions. Although narrative reviews tend to be subjective and are limited by sources of bias, they continue to have an important place in the medical literature, particularly for gaining background knowledge and an expert's views regarding a subject. Readers should recognize that narrative reviews are almost exclusively produced by proponents for test utilization. 12 Systematic reviews are a most valuable EBLM tool. Systematic reviews di¡er substantially from narrative reviews in that they are focused, structured and address speci¢c questions about health-care issues of diagnosis, screening, treatment, monitoring and preventive services. They use de¢ned methods and speci-¢ed strategies to locate, evaluate and compile scienti¢c evidence that is then objectively included or excluded. Systematic reviews are frequently prepared by investigators who are expert at performing reviews, rather than experts in the speci¢c topic area being investigated. Use of the systematic approach can help to minimize bias and random error; the speci¢c methods used are documented in the methods section of the review so that the research can be evaluated and replicated. Systematic reviews incorporate summaries of data, which include evidence tables and ¢gures whenever possible. Perhaps the most important of these summaries is the meta-analysis, which entails statistical analysis of results from similar but independent primary studies meeting speci¢c and clearly stated aims and criteria. Meta-analysis represents a quantitative summary with statistical synthesis of multiple studies to produce an overall estimate and uncertainty for a well-de¢ned research question in a speci¢ed patient population. Meta-analysis is considered a scienti¢c endeavour and is used whenever appropriate as a method for examining data in systematic reviews.
The goal of systematic review is to present thoughtful interpretation of best evidence in a way that clari¢es what is known from what is speculated, identi¢es sources of inconsistency and aids in development of research questions. Proper systematic review addresses key questions by limiting the e¡ects of bias, integrating relevant information from available evidence, distilling data to manageable levels and identifying limitations in methodology. A caveat worthy of note is that systematic reviews frequently fail to adequately assess the Spectrum bias: Evaluation of the test in a population that is not representative of that for which the test will be used. Exaggeration of test accuracy can result, such as when the test is evaluated in patients with the disease of interest, and healthy patients (rather than all patients for whom the test would normally be considered).
Bias due to inappropriate reference test:
The reference test does not represent the best-available comparator. This leads to underestimation of test accuracy, the degree of which depends on the disease prevalence in the target condition.
Review bias: When the investigator is not blinded to results of the index test or the reference test. This leads to overestimation of test accuracy, particularly if results are in any way subjective.
Partial verification bias: Some subjects with a negative index test result are not subject to the reference test. These patients will be assumed to be true negatives and the number of false-positive results will be underestimated. This leads to incorrect assessment of sensitivity and specificity.
Differential verification bias: Some subjects with negative test results are not subject to the 'gold standard' test, but undergo a different reference test. This may lead to overestimation of test accuracy.
Incorporation bias:
The index test result is combined with the reference test and forms part of the gold standard. This leads to overestimation of test accuracy.
Indexing bias (or publication bias):
The effect that positive studies are more likely to be published in journals that are indexed in Medline and other services than negative studies.
Language bias: Studies showing positive results are more likely to be published in English language journals and are more likely to be cited and published repeatedly.
methodological quality of primary studies and take that quality into account in the interpretation of results. Strategies for assessment of methodological quality by systematic reviews are still in their infancy and there is substantial room for improvement. 14 
Trial design
All clinical studies involve a determinant that is the topic of study and evaluated for its e¡ect on an outcome. In the context of therapeutics, the determinant is a treatment or intervention; in laboratory medicine, the determinant involves information. Not surprisingly, investigation of these diverse types of determinants is driven by di¡erent questions, and therefore the optimal trial design for laboratory tests may di¡er from those for examining the e⁄cacy of therapeutics and medical devices. The outcome selected for either laboratory medicine or therapeutic trials must be relevant to the question, and can be evaluated either by cross-section or longitudinally. As the names imply, cross-sectional studies are analogous to a 'snapshot', where the determinant and outcome are evaluated at a single point in time. Longitudinal studies involve evaluation of outcomes over a speci¢ed time period. Randomized controlled trials (RCTs) are studies in which at least one 'test' treatment, intervention or provision of information is compared with a control group that receives placebo, no (or a di¡erent) intervention, or no (or di¡erent) information. In studies of therapeutics and interventions, the RCT design is superior for comparing treatments because it avoids bias and uses a concurrent comparison group (controls) to compensate for any trends over time. In laboratory medicine, the common question addressed in RCTs is 'does the information provided by the test alter the outcome compared to not having that information available'. As indicated in Figure 3A , from the pool of possible patients screened, those enrolled are concurrently assigned to either the test or control arms; subjects in both arms are completely followed up. Characteristics of a welldesigned RCT include: (1) an appropriate randomization procedure for unbiased allocation of patients to the test or control arm; (2) an appropriately sized sample to provide the statistical power to allow meaningful comparison; (3) an intention-to-treat analysis to evaluate both similarity of the patients assigned to di¡erent groups and non-compliance or deviations from policy by clinicians; and (4) statistical results that include a speci¢c P-value with a speci¢ed con¢dence interval to quantify uncertainty. Outcomes can be diagnosis (cross-sectional), adverse clinical events over a period of time (longitudinal), or economic. Provided the patient enrolment criteria, aims and outcomes are similar, data from RCTs may be pooled for metaanalyses to generate a more accurate and precise estimate of the e¡ect of the treatment, intervention or laboratory testing.
Observational or cohort studies are not designed to alter or in£uence patient or practitioner behaviour. Care-givers are blinded to results for the index test. As outlined in Figure 3B , potential subjects are evaluated, enrolled and monitored either prospectively or retrospectively during their episode of care and no e¡ort is made to alter testing strategy. Outcomes can either be cross-sectional --such as diagnostic performance --or longitudinal, for example comparison of one-year mortality. Observational studies provide useful information about care patterns and patient preferences, and are also useful for generating hypotheses for future studies. However, these studies can be susceptible to patient selection bias and may lead to inaccurate conclusions about the comparative bene¢t of testing strategies. This can be, in part, because observational studies may be comparing patient groups with di¡erent prognoses due to temporal trends in disease characteristics, diagnostic methods or supportive care.
Case--control designs are by de¢nition retrospective. As indicated in Figure 3C , a subset of cases having the outcome of interest and a subset of controls who do not are identi¢ed from the study population. They are matched for age, gender, race, clinical history and other important demographic parameters. The index test is then measured in case:control ratio of 1:1, 1:2, or 1:3 depending on the question addressed and prevalence of the target outcome. Case--control studies can assess outcomes either by cross-sectional design, for example to determine the accuracy of test, or longitudinally, for example to investigate how well an index test has predicted the long-term outcome. Case--control studies are more e⁄cient than RCTs or cohort studies. This is because subjects are selected based on the presence or absence of the outcome or target condition rather than determinant (as in RCTs) or by chance (as in cohort studies). Also, case--control studies are retrospective, so they take less time to perform, particularly for investigation of rare outcomes. There are, however, several limitations associated with the case--control design, including the fact that selection of appropriate matched controls may be di⁄cult. Often, data may be missing in a signi¢cant number of subjects, and sometimes this impacts on the two groups of subjects to a di¡erent degree. This complicates statistical analysis intended to compensate fully for di¡erences between cases and controls. From the patient's perspective, any damage has already occurred because case--control studies are retrospective. Case--control studies are usually considered for investigation or hypothesis generating, rather than a de¢nitive form of research such as RCTor cohort study. 15 However, there are a number of situations in which they are the main type of study design, for example the e¡ect of noxious materials on subjects.
There are examples of how the impact of tests can be investigated by RCT, observational study or case-control study. 16--18 Alternatively, diagnostic studies may also aim at comparing two or more tests or testing strategies. The fundamental issue for establishing or comparing performance is the designated reference method. Unfortunately, in many cases, a true reference method does not exist and an imperfect standard must be utilized. Although statistical methods are well de¢ned for assessing the accuracy of a new diagnostic test compared with reference method, similar methods are sparse in a setting where a reference standard is unavailable. 19 The challenge is to ¢nd a comparator as close as possible to the theoretical reference method because accurate assessment of a new test may be compromised when an inappropriate reference strategy with its own uncertainty of estimation (e.g. a subjective test) is used. Further, the use of a reference standard may be limited if the new test is more accurate than the reference, the reference test is very expensive or invasive or use of the reference in all patients may be unethical. Table 4 summarizes key domains that should be included by systematic reviews as well as RCTs, observational studies and diagnostic test studies. 20 
Translation of diagnostic data
Measures of diagnostic performance
Diagnostic accuracy is the agreement between the index test and a reference standard. Laboratory tests are frequently used to discriminate subjects with a target disorder from subjects without it. Results for laboratory tests are usually most valuable when they are considered a continuous variable, the magnitude of which re£ects the probability of diagnosis, continuum of disease severity or possibility of adverse outcome. In laboratory medicine, appropriately powered data-sets for considering tests as continuous variables are not the rule; for this reason, decision points or 'cut points' are frequently developed which serve to convert ('dumb As displayed in Table 5 , diagnostic performance can be expressed in several ways including sensitivity and spe-ci¢city and the associated expressions for positive predictive value (PPV) and negative predictive values (NPV). Reporting imprecision of these measures as the 95% con¢dence interval (95% CI) is essential for interpretation. PPV and NPV are usually of keen interest to clinicians because they address the following questions: 'What is the probability that my patient has the target condition when the test is positive (PPV)?' and/or 'What is the probability that my patient with a negative test result has the target condition (NPV)?' Sensitivity and speci¢city are not a ¢xed property of a test in all patient populations, but are dependent on the group in which the test is used. PPVand NPVare highly dependent upon the prevalence of disease in the population examined. This point is illustrated in the following example.
Example 1
A new test for rheumatoid arthritis (RA) is developed in which diagnostic sensitivity is 99% and diagnostic speci¢city is 99%. What is the PPV of the test in the following patient care settings? (A) A rheumatology clinic in which the prevalence of the RA is 50%. Discussion: In 10,000 clinic patients, 5000 will truly have RA and 5000 will not. Of the 5000 true RA patients, 4950 tested positive for the test (because the sensitivity is 99%, i.e. 1% false-negative rate) and of the 5000 non-RA patients 50 tested positive (because the speci¢city is 99%; i.e. 1% false-positive rate). Therefore, PPV ¼ 4950/ (4950 þ50) ¼ 99%, and NPV ¼ 4950/(4950 þ50) ¼ 99%.
(B) A group of 18-year-old students at a school health fair in which the prevalence of RA is 1%.
Discussion: In the 10,000 18 year olds, a prevalence of 1% means that only 100 individuals will truly have RA and the remaining 9900 will be non-RA. Of the 100 RA individuals, there will be 99 that test positive for the test and one false negative (because the sensitivity is 99%). Of the 9900 non-RA patients, there will be 99 that test falsely positive (because the speci¢city is 99%). Therefore, PPV ¼ 99/(99 þ99) ¼ 50%, and the NPV ¼ 9801/ (9801 þ1) ¼ 99.99%
This example illustrates that even a test with excellent diagnostic sensitivity and speci¢city can show dramatically di¡erent PPVand NPV, dependent entirely on the disease prevalence. Table 6 shows expressions for positive and negative likelihood ratios, and the diagnostic odds ratio. By using Bayes theorem, it is possible to calculate the post-test probability with knowledge of the pre-test probability and the likelihood ratio. 21 The expression for Bayes theorem is Post-test Odds ¼ Pre-test Odds Â Likelihood Ratio For this purpose, pre-test probability, or prevalence, must be converted to pre-test odds using the formulae: pre-test odds ¼ prevalence/(1--prevalence). Once the post-test odds are calculated, conversion to post-test probability is possible with the following: Post-test probability ¼ post-test odds/(1 þpost-test odds). This is done because humans are accustomed to thinking in terms of decimals and percentages, so generally results are easier to comprehend as a post-test probability rather than post-test odds.
Example 2
A clinician asks 'What is the probability that my patient with dyspnoea in our Emergency Department has a diagnosis of congestive heart failure (CHF) if the B-type natriuretic peptide (BNP) test is below the cut point (i.e. the test is negative)?' Discussion: Given the prevalence of CHF in the Emergency Department population is 25%, the pre-test odds ¼ prevalence/ (1Àprevalence) ¼ 0.25/0.75 ¼ 0.33. If the sensitivity of BNP for CHFin ED patients with dyspnea is 93% and the speci¢city is 85%, then the negative likelihood ratio ¼ 0.07/0.85 ¼ 0.082. Thus the post-test odds ¼ pre-test odds Â negative likelihood ratio ¼ 0.33 Â 0.082 ¼ 0.026. Converting post-test odds to post-test probability ¼ post-test odds/(1 þpost-test odds) ¼ 0.026/(1 þ0.026) ¼ 0.025
Positive and negative likelihood ratios are clearly useful; however, often it is more convenient to report test performance as a single indicator in meta-analysis and other applications. This need for a single indicator is the purpose of the diagnostic odds ratio, because it expresses diagnostic performance as a single term and is particularly useful when comparing the performance of competing tests. Comparing competing tests using paired indicators, such as sensitivity and speci¢city, can be complicated especially if one test does not outperform the other on both indicators. 22 For this reason, reporting the diagnostic odds ratio is a preferred means for reporting test performance. 22 As displayed in Table 6 , the diagnostic odds ratio includes the same terms as sensitivity, speci¢city, PPV and NPV. As alluded to above, use of the diagnostic odds ratio facilitates formal meta-analysis of studies on diagnostic test performance, and it can be derived from logistic models, which allow for the inclusion of additional variables to correct for heterogeneity. 19 However, one drawback of the use of diagnostic odds ratio must be noted. This expression ( Table 6 ) does not allow for deriving the true-positive and false-positive rates separately; therefore, calculation of sensitivity, speci¢city, NPV, PPV or positive and negative likelihood ratios is not possible directly from the diagnostic odds ratio. Reporting the 95% CI for the likelihood ratios and diagnostic odds ratio allows truer interpretation of test performance.
Receiver operator characteristic curves
As shown in Figure 4A , ROC curves are plots of sensitivity on the y-axis versus (1Àspeci¢city) on the x-axis. ROC curves are derived from data in which the index test is performed on a patient population who had a predetermined binary outcome. Outcomes may include yes/no for a disease diagnosis as in a cross-sectional study, prognosis such as one-year mortality in longitudinal studies, yes/no for occurrence of adverse events, presence or absence of a combined endpoint, or an outcome such as re-hospitalization over a speci¢ed time period. An actual plot of the data from which the curve is derived adds insight to information provided by ROC analysis. Figure 4B shows an example of B-type natriuretic peptide data in a cohort of patients evaluated for a diagnosis of CHF or no CHF. 23 The associated ROC curve ( Figure 4A ) was constructed by evaluating the sensitivity and (1Àspeci¢city) of the cohort for the diagnostic outcome at each BNP result in the continuum of BNP values 0 through N. The arrows in Figure 4 indicate the corresponding points on the ROC curve (panel A) and data plot (panel B) that best separates the CHF and no CHF groups; this optimum decision point confers the minimum number of false positive and false-negative results. Note that on the ROC curve the optimum point is located at the curve location closest to the upper-left hand corner of the plot (100 pg/mL in this example). Further, the overall performance of the test can be determined from the area under the ROC curve, also termed the C-index. 24 The imprecision of the ROC curve can be calculated and provides insight regarding reliability of the results. 25 Poor or useless tests have ROC curve areas close to 0.50, and the plot appears as a diagonal where (sensitivity ¼1Àspeci¢city). For an excellent test, the ROC curve rises steeply and passes close to the upper lefthand corner; the perfect test has an area of 1.0, and both the sensitivity and speci¢city are 100%.
The example in Figure 4A has listed an ROC area (C-Index) of 0.93 (95% CI: 0.89--0.96). It is important to note that imprecision is not equivalent across the full range of values. This is because in many cases the data comprising the ROC curve are either at the low end or high end of the continuous range of values. Typically, there are relatively few results near the cut point, so imprecision at this most important part of the ROC curve tends to be larger. This is another reason why showing the actual data distributions of data can add valuable insight to interpretation.
Depending upon the binary outcome and patient population, ROC curves can be used for diagnostic, monitoring and prognostic applications in laboratory medicine. For example, analysis of ROC curve areas is larger ROC area has the better performance. ROC curve areas have also been used to compare timing of laboratory tests after an event. For example, with later sampling, cardiac troponin performance improves compared with collection at clinical presentation or near to the time of symptoms onset. 26 There are several caveats regarding the use of ROC curves for assessment of diagnostic performance. First, understanding details of the patient population included and the binary outcome is critical for proper interpretation of ROC curve data. The study must be su⁄ciently powered to investigate and address the stated aims. Also, appropriate measures must be taken to minimize patient spectrum bias and other similar sources of potential error.
As described earlier, meta-analyses of test accuracy studies involve the computation of a weighted average of individual study results, which can improve the precision of accuracy estimates and reveal di¡erences between studies that impact test performance. Metaanalysis is appropriate for studies of high methodological quality that investigate the same therapeutic e¡ect or diagnostic performance in similar cohorts of patients. An improvement in the precision for estimating the true diagnostic performance of a test should, therefore, result because all of the variability observed can be attributed to random variation. Therefore, metaanalysis should only be considered if the patients are from the same clinical populations and settings and if similar index and reference tests are included.
Summary ROC curves can be useful for detecting heterogeneity of meta-analysis data. The approach of Moses et al. 27 is straightforward and involves expressing data for each study as a diagnostic odds ratio and noting whether this ratio is related to the proportion of patients in the study having positive results. This positivity is important because it may indicate the presence of a phenomenon termed the 'threshold e¡ect', which may be present if di¡erent de¢nitions of positive or different cut points are used in the studies included in the meta-analysis. The possibility of a threshold e¡ect can be investigated statistically and through plotting summary ROC curves (see 'presentation of data'). Detailed discussion of methodological issues involved in metaanalysis is considered elsewhere. 19 
Clinical trials and actual practice: expectations versus reality
Clearly, bias in clinical trials can lead to overstatement of diagnostic performance. 7 However, it must also be recognized that results from clinical trials are likely to show the most optimistic performance of the test. This is in part due to design; frequently, patients with confounding conditions such as renal insu⁄ciency, hepatic injury, and other comorbidities are excluded from the trial. Also, the process of enrolment involves patient informed consent, which is necessarily a selection process, and resources for obtaining consent are often unavailable after normal working hours. These issues and others open the possibility of patient spectrum bias in most clinical trials. For this reason, clinical trial populations may not be representative of 'real life'. A sub-study analysis of the 'Breathing Not Properly'study, which investigated the degree to which BNP added to the clinical judgement of Emergency Medicine physicians for the diagnosis of heart failure, is a good example. From the information supplied, 46.9% and 25.4% of the enrolled patients were classi-¢ed as high (480%) or low (o20%) pre-test probability of having a diagnosis of CHF; thus, only 27.8% of the patients were listed as having intermediate probability of CHF. 28 In actual practice, the patients having intermediate probability represent a far greater proportion of total, and those with high or low pre-test probability may not have BNP requested. 28 This is re£ected in ROC curve areas also. The 'Breathing Not Properly' study reported an ROC curve area of 0.91 (95% CI: 0.90--0.93) for the diagnosis of CHF. 29 A community cohort of similar patients that included all patients with enrolment criteria showed a far lower ROC curve area of 0.73 (95% CI: 0.76--0.70) for the CHF diagnosis. 30 This di¡erence in ROC curve area, of course, lowers the diagnostic accuracy of the test in actual practice by about 15%. This is consistent with literature on this subject, which estimates that performance in routine utilization diminishes 15--20% compared to clinical trials. 31 
Displaying the results of data
The most valuable output for primary studies, metaanalysis and systematic review is the summary data and its interpretation. Therefore, if data are not expressed in a way that is clear and comprehensible to readers and investigators, much of the impact of the study or report may be lost.
An e¡ective way to display data for meta-analysis and systematic reviews is by use of 'Forest plots', illustrated in Figure 5 . As shown in this example for use of BNP for diagnosis of CHF, Forest plots can display sensitivity ( Figure 5A ), speci¢city ( Figure 5B ) or diagnostic odds ratio ( Figure 5C ). 31 The convention is to show the median as a black dot with the 95% CI indicated as lines. Summary values are indicated by diamonds, the widths of which indicate the imprecision from pooling the studies. 32 Calculation of post-test probability when the likelihood ratio is known requires conversion of the pre-test probability into pre-test odds and then back to post-test odds. Finally, post-test odds can be converted to posttest probability for easier interpretation, as illustrated in Example 2 above. Although these formulae and calculations are straightforward, an excellent visual aid to facilitate direct transformation of pre-test probability and likelihood ratio values to post-test probabilities is termed the Fagan nomogram; this nomogram is displayed in Figure 6 . Fagan's nomogram allows this conversion by simply connecting a line from the pre-test probability (or prevalence) through the likelihood ratio (positive or negative depending on the question) to estimate the post-test probability. 33 
Example 3, use of Fagan's nomogram
Question: Is BNP for diagnostic use in patients arriving to the urgent care setting most useful for ruling-in decompensated heart failure (DHF) or for ruling-out DHF?
Discussion: From the Breathing Not Properly Study, the prevalence of DHF is 0.50. 29 Also from this study, the diagnostic sensitivity of BNP is 90.0% and the speci¢city is 76.0%. The positive likelihood ratio is calculated as 3.74; the negative likelihood ratio is 0.13. Using the Fagan's nomogram in Figure 6 , if the BNP test is positive Figure 5 Forest plots of sensitivity, specificity and diagnostic odds ratio for BNP use in the diagnosis of CHF from meta-analysis (adapted from reference 32) (4100 pg/mL), the pre-test probability increases from 0.5 to 0.75. However, if the BNP test is negative (o100 pg/mL) with the same clinical scenario, then the post-test probability is 0.11. Thus using the optimum cut point of 100 pg/mL, the test is most useful for ruling out DHF.
In the future, modes such as Fagan's nomogram will become more important for clearly presenting information to clinicians for interpretation.
Earlier it was stated that whenever data allow, laboratory tests should be considered continuous variables rather than binary positive and negative values. This is because the magnitude of the increase (or decrease) frequently re£ects the probability of diagnosis, continuum of disease severity or possibility of adverse outcome. Figure 7 shows a modi¢ed version of Fagan's nomogram that allows simple conversion of continuous data to post-test probability. 28 Using example 3 above, if the BNP value was150 pg/mL, then a line can be connected from the 0.5 prevalence through the BNP value (150 ng/mL) to estimate the post-test probability at about 0.58 (Figure 7) . However if the 'positive' BNP value was 800 pg/mL, then from Figure 7 the posttest probability raises to 0.93, demonstrating that the concentration of BNP increase is an important consideration.
As noted previously, ROC curves are particularly useful for comparing the performance of two tests; this is done by performing both assays on a single relevant cohort of patients and statistically analyzing the di¡erence in the ROC areas for the tests. If one test shows a signi¢cantly larger area, then it is a better test for evaluating the outcome in the cohort tested. If there is no signi¢cant di¡erence between the two tests, then the tests do not di¡er in their ability to predict the outcome. Figure 8 shows an example comparing ferritin and transferrin for the diagnosis of iron de¢ciency anaemia. 34 As mentioned previously, summary ROC curves can be of assistance in displaying data from meta-analysis and systematic reviews and for examining the heterogeneity of data introduced by phenomenon such as use of di¡erent test thresholds and cut points. Sensitivity and speci¢city are frequently traded depending on the clinical application and study. Figure 9 shows a Forest plot (panel A) and summary ROC curve from a metaanalysis examining the use of D-Dimer for diagnosis of pulmonary embolism in the Emergency Department. 35 The points highlighted on the summary ROC curve (panel a) are also shown on the Forest plot (panel b). Note that in panel b, the sensitivity and speci¢city for these 'outlier' primary studies have the most extreme values for sensitivity and speci¢city on the Forest plot, suggesting that di¡erent threshold values were used. This heterogeneity can be evaluated statistically to determine signi¢cance. 19 ROC curves add great insight into interpretation of laboratory tests. However, a single ROC curve can evaluate the designated outcome at one time only, and is unable indicate variation or dependence of the outcome with time. A typical way to illustrate the proportion of patients surviving at any time is termed the Kaplan--Meier survival curve. The Kaplan--Meier curve also allows illustration and comparison of di¡erent groups on the same curve. Figure 10 shows survival curves for di¡erent concentrations of N-terminal proBNP in acute coronary syndrome patients enrolled in the GUSTO IV trial. 36 Note that most of the deaths occurred in the 30-to 60-day period after enrolment into the trial.Whereas ROC curves would evaluate outcome at 360 days only, Kaplan--Meier curves allow visualization of the trend in outcome and assessment at any time point during follow up.
Incorporating ROC curves and likelihood ratios into clinical laboratory reports in a way that is comprehensible can be very challenging. This incorporation would be very valuable, however, because lab output typically includes only the analyte result along with the reference interval. This presentation is common even though it is known that the magnitude of the increase or decrease for many analytes directly relates to the likelihood of disease or outcome. (a) The summary ROC curve for the meta-anlaysis. 35 (b) The Forest plots and summary sensitivity and specificity. The broken circles and triangles highlight corresponding points from the ROC and Forest plots that may be outliers
Example 4, indicating likelihood ratios in laboratory reports
Question: A patient presents to clinic exhibiting clinical symptoms and signs suggestive of iron de¢ciency anaemia. The attending clinician knows that ferritin is a useful test in the context of this condition and requests a ferritin measurement. The laboratory result is 32 mg/L (reference interval: 20--250 mg/L). The clinician notes that this value is clearly within the reference interval, but wonders how likely it is that the patient still has iron de¢ciency anemia with a ferritin value of 32 mg/L. Discussion:The top portion of Table 7 shows how results might typically be reported. 37 The entire table shows an example of how ferritin results could be reported in the context of iron de¢ciency anemia. In this example, the patient's ferritin result is 32 mg/L; this value could mislead the clinician into ruling out the disease if only the information at the top of Table 7 is reported. However, inclusion of the interpretive data in Table 7 allows the clinician to note that the patient's result is associated with a likelihood ratio of nearly 5. Thus, there is an 'intermediate high risk' for the diagnosis of this disease, even though the result is within the reference interval.
Guidelines
The establishment of clinical guidelines is as an important element of initiatives to enhance the quality of patient care. 38 They represent a systematic means for developing care pathways, which enables stakeholders to identify relevant clinical questions and establish evidence-based strategies to improve outcomes.
(a) Where to find guidelines? should be built on one or more well-performed systematic reviews on the topic. If no systematic reviews exist, the group must produce one or two. Whether performing a review or appraising published ones, attention must be directed to the category of evidence supporting each conclusion, as 36 There is a significant difference between the curves as calculated by the log rank 36 this will a¡ect the strength of recommendations made in the guidelines. (d) Translate evidence into guideline and grade the strength of recommendations. After gathering and analyzing the evidence, the guideline group must make recommendations based on the evidence. Recommendations may either follow directly from clinical studies or be extrapolated from the results of studies. (e) Obtain external overview and update the guidelines. It is recommended that guidelines be reviewed by experts in the clinical content area, experts on systematic reviewing and guideline development, and potential users of the guidelines. New evidence may outdate guidelines relatively quickly; thus, determining a date when the guidelines will be reviewed for updates is important.
The establishment of guidelines also provides an incentive to critically review data on the utility of a test or intervention. The holistic nature of a guideline also helps to identify the way in which practice may need to change when implementing a new test or intervention. A guideline also provides an overview of the quality of the evidence which indicates how robust the data are, e¡ectiveness of a test and how wide the applicability of the test might be in di¡erent clinical settings. 39 Although much of the information will have been generated from the peer-reviewed literature, guidelines must allow for potential applications that are unsupported by adequate evidence, but supported by expert opinion or consensus.
Guidelines can provide an important foundation for the education of users of a service as well as providing the benchmark against which to audit the successful implementation of a service. In this way, a guideline can become a platform for maintaining good clinical governance. 40 However, studying the success of guideline implementation and evidence of best practices is very challenging and several barriers have been identi-¢ed. 41 An important barrier is that properly powering quality improvement studies is di⁄cult. It is noteworthy that the 'unit' being studied is the provider of patient care, which greatly complicates design and analysis of these studies. A second challenge is the de¢nition of a'usual care'group for comparison with a group after intervention. During the baseline period when usual care is de¢ned, care-givers are aware that a study is being conducted. Perhaps the only way to study the intervention's impact is to use a similar medical centre that did not undergo the change. However, to match the intervention centre exactly is very di⁄cult. Finally, one must ask how long it takes to change practice in an institution. This information is key for determining when studying the e¡ect of the practice changes should be assessed. Overall, knowledge is needed on how to e¡ectively study the dissemination of highquality evidence so that patients can receive the very best care. 41 
Clinical audit
The goal of clinical audit is collection of data to assess how the test or strategy is actually used in practice and whether utilization is e¡ective for diagnosis or disease management. Another purpose of the clinical audit is to validate that the assumptions made with the initial evaluation and implementation were correct. In a typical quality improvement strategy, the audit comes after the development of a clinical pathway in which the test plays a role. However, an audit may be aimed at improving a process or the outcome of a process (e.g. exploring factors responsible for a delayed turnaround time). The clinical audit may be used for assessing compliance with guidelines in order to validate the impact on clinical care. At the institutional level, the clinical audit is an essential part of quality assurance according to national regulatory bodies. Therefore, the audit cycle has become an essential part of institutional organizations to ensure that the process and ¢ndings are used to improve daily practice.
Conducting a clinical audit involves routine tracking of numbers, satisfaction surveys and other data collection tools. A complete audit cycle includes setting a target, a threshold or standard consistent with meeting the target and then observing, evaluating, reporting and implementing modi¢cations based on the data prior to starting a new cycle. To maximize the e¡ectiveness of an audit, garnering the support of all stakeholders involved in the processes to be studied is essential. Seeking input from colleagues and sta¡ in the design and implementation of the audit is usually a successful tactic.
The collaborative clinical audit can also be a valuable tool for utilizing data to educate care-givers and help foster compliant behaviour. The commitment to audit and quality assurance is conducive to increased professional satisfaction. This activity also demonstrates that care path development and working together is a productive use of time and improves satisfaction with laboratory services and patient care.
Conclusion
Utilization of evidence-based techniques cuts across all clinical areas and must be a part of modern laboratory medicine practice. Succinctly stating the question in a structured way assists in searching the literature to ¢nd the best-available information. The information can be from meta-analysis, systematic reviews or primary studies. Output can be stated in terms of sensitivity, speci¢city, positive or likelihood ratios or diagnostic odds ratios. Tools such as Forest plots, ROC curves or nomogram presentations such as Fagan's diagram can assist in communicating information. Being cognizant of how laboratory medicine data are utilized by clinicians is critical. Evidence-based guidelines should be carefully considered to help with the development of care paths in institutions. Once implementation of tests and testing strategies are implemented, auditing performance is useful for assuring compliance and objectively evaluating the impact.
